The Motley Fool's health-care show, Market Checkup, focuses this week on cholesterol, one of America's most notable health-care concerns.
According to the CDC, approximately 71 million Americans have high cholesterol, and less than 50% actually get treated. High levels of LDL cholesterol, commonly known as "bad" cholesterol, can lead to dangerous health problems, including heart disease and high blood pressure. In the following segment, health-care analysts David Williamson and Max Macaluso discuss how sales of AstraZeneca's (NYSE:AZN) cholesterol-lowering statin Crestor are threatened by competing generic drugs.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.